- Home
- APTV vs RPRX Comparison
APTV vs RPRX Comparison
Compare APTV & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APTV
- RPRX
- Stock Information
- Founded
- APTV 2011
- RPRX 1996
- Country
- APTV Switzerland
- RPRX United States
- Employees
- APTV N/A
- RPRX N/A
- Industry
- APTV Auto Parts:O.E.M.
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- APTV Consumer Discretionary
- RPRX Health Care
- Exchange
- APTV Nasdaq
- RPRX Nasdaq
- Market Cap
- APTV 15.3B
- RPRX 13.9B
- IPO Year
- APTV 1999
- RPRX 2020
- Fundamental
- Price
- APTV $70.48
- RPRX $36.24
- Analyst Decision
- APTV Buy
- RPRX Strong Buy
- Analyst Count
- APTV 19
- RPRX 3
- Target Price
- APTV $77.93
- RPRX $48.33
- AVG Volume (30 Days)
- APTV 2.5M
- RPRX 3.8M
- Earning Date
- APTV 07-31-2025
- RPRX 08-07-2025
- Dividend Yield
- APTV N/A
- RPRX 2.43%
- EPS Growth
- APTV N/A
- RPRX 37.60
- EPS
- APTV 6.35
- RPRX 2.45
- Revenue
- APTV $19,637,000,000.00
- RPRX $2,263,845,000.00
- Revenue This Year
- APTV $1.92
- RPRX $29.35
- Revenue Next Year
- APTV $4.70
- RPRX $7.58
- P/E Ratio
- APTV $11.12
- RPRX $14.77
- Revenue Growth
- APTV N/A
- RPRX 1.13
- 52 Week Low
- APTV $47.19
- RPRX $24.05
- 52 Week High
- APTV $80.95
- RPRX $36.56
- Technical
- Relative Strength Index (RSI)
- APTV 55.84
- RPRX 61.10
- Support Level
- APTV $69.16
- RPRX $35.51
- Resistance Level
- APTV $72.71
- RPRX $36.56
- Average True Range (ATR)
- APTV 1.70
- RPRX 0.65
- MACD
- APTV -0.15
- RPRX -0.06
- Stochastic Oscillator
- APTV 58.14
- RPRX 79.35
About APTV Aptiv PLC
Aptiv PLC signal and power solutions segment supplies components and systems that make up a vehicle's electrical system, including wiring assemblies and harnesses, connectors, electrical centers, and hybrid electrical systems. The operating segments are grouped on the basis of similar product, market and operating factors: Signal and Power Solutions, which includes complete electrical architecture and component products. advanced Safety and User Experience, which includes vehicle technology and services in advanced safety, user experience, and smart vehicle computing and software, as well as cloud-native software platforms, autonomous driving technologies, and DevOps tools. Eliminations and Other.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.